Location History:
- East Hanover, NJ (US) (2008 - 2015)
- Boonton, NJ (US) (2016)
Company Filing History:
Years Active: 2008-2016
Title: **Innovative Contributions of Inventor Wajiha Khan**
Introduction
Wajiha Khan, an accomplished inventor based in East Hanover, NJ, has made significant strides in the field of pharmaceutical innovations. With a portfolio of six patents to her name, she has focused primarily on therapeutic compounds that target critical biological interactions.
Latest Patents
Among her notable inventions are several groundbreaking patents. One of her latest patents involves "Cell penetrating peptides to target EIF4E." This invention provides compounds that disrupt the eIF4E-eIF4G interaction, utilizing cell-penetrating peptides that bind to the mammalian initiation factor eIF4E. These peptides consist of amino acid sequences selected from specific groups, ensuring effective interaction with human initiation factor eIF4E. Additionally, she has developed "Glucose-dependent insulinotropic peptide analogs," which are compounds that function as agonists of the GIP receptor, showcasing her innovative approach to enhancing diabetes treatments.
Career Highlights
Wajiha Khan is currently affiliated with Hoffmann-La Roche Inc., where she applies her expertise in pharmacology and biochemistry to develop novel therapeutic solutions. Her role at the company enables her to work on innovative projects that have the potential to improve patient care and treatment outcomes in various diseases.
Collaborations
Throughout her career, Wajiha has collaborated with talented colleagues, including Waleed Danho and Joseph Swistok. These partnerships foster a vibrant exchange of ideas and contribute to advancing research in their respective fields, enhancing the impact of their innovations.
Conclusion
Wajiha Khan continues to be a driving force in the area of pharmaceutical development, expertly navigating the complexities of drug interactions and therapeutic innovations. Her contributions not only exemplify her skills as an inventor but also hold promise for the future of medical treatments, particularly in addressing critical health challenges.